Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10301932 | 0.96 | CNR2 (0.33) | CNR2CNR1MAPTTDP1GABRA1 | |
| SCHEMBL12735607 | 0.92 | CNR2 (0.35) | CNR2CNR1GABRA1GABRB2CTSL | |
| SCHEMBL12740120 | 0.92 | CNR2 (0.35) | CNR2CNR1GABRA1GABRB2CTSL | |
| SCHEMBL10301931 | 0.89 | CTSS (0.37) | CNR2MAPTGABRA1GABRB2CTSL | |
| SCHEMBL12735599 | 0.88 | FFAR4 (0.35) | CNR2CNR1GABRA1GABRB2CTSL | |
| SCHEMBL12740118 | 0.88 | FFAR4 (0.35) | CNR2CNR1GABRA1GABRB2CTSL | |
| SCHEMBL10301926 | 0.88 | CNR2 (0.37) | CNR2CNR1CTSLCTSSCTSK | |
| SCHEMBL12738863 | 0.88 | CYP11B1 (0.34) | CNR2CNR1GABRA1GABRB2 | |
| SCHEMBL14766600 | 0.87 | CNR2 (0.43) | CNR2CNR1MAPTGABRA1GABRB2 | |
| SCHEMBL14766295 | 0.87 | CNR2 (0.43) | CNR2CNR1MAPTGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | CNR2 2145/4885CNR1 1338/4885MAPT 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.